ERAS

ERAS

USD

Erasca Inc. Common Stock

$1.520-0.060 (-3.797%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$1.580

High

$1.615

Low

$1.515

Volume

1.46M

Company Fundamentals

Market Cap

430.6M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

1.73M

Exchange

NMS

Currency

USD

52-Week Range

Low $1.01Current $1.520High $3.45

Related News

Analyst Upgrades

Raymond James Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $5

Raymond James analyst Laura Prendergast initiates coverage on Erasca with a Outperform rating and announces Price Target of $5.

View more
Raymond James Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $5
GlobeNewswire

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors,

View more
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Analyst Upgrades

Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3

Goldman Sachs analyst Chris Shibutani maintains Erasca with a Buy and lowers the price target from $3.5 to $3.

View more
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $6 Price Target

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca with a Buy and maintains $6 price target.

View more
HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $6 Price Target
Analyst Upgrades

Morgan Stanley Assumes Erasca at Overweight, Maintains Price Target of $4

Morgan Stanley analyst Jeffrey Hung assumes Erasca with a Overweight rating and maintains Price Target of $4.

View more
Morgan Stanley Assumes Erasca at Overweight, Maintains Price Target of $4